Curran A - Search Results

1

Management of tuberculosis in HIV-infected patients.

Curran A, Falcó V, Pahissa A, Ribera E. Curran A, et al. AIDS Rev. 2012 Oct-Dec;14(4):231-46. AIDS Rev. 2012. PMID: 23258298 Review.

2

Double-boosted protease inhibitor antiretroviral regimens: what role?

Ribera E, Curran A. Ribera E, et al. Among authors: curran a. Drugs. 2008;68(16):2257-67. doi: 10.2165/0003495-200868160-00001. Drugs. 2008. PMID: 18973392 Review.

3

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

Imaz A, del Saz SV, Ribas MA, Curran A, Caballero E, Falcó V, Crespo M, Ocaña I, Diaz M, de Gopegui ER, Riera M, Ribera E. Imaz A, et al. Among authors: curran a. J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):382-6. doi: 10.1097/QAI.0b013e3181b17f53. J Acquir Immune Defic Syndr. 2009. PMID: 19654552

4

HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain.

Mothe B, Perez I, Domingo P, Podzamczer D, Ribera E, Curran A, Viladés C, Vidal F, Dalmau D, Pedrol E, Negredo E, Moltó J, Paredes R, Perez-Alvarez N, Gatell JM, Clotet B. Mothe B, et al. Among authors: curran a. Curr HIV Res. 2009 Nov;7(6):597-600. doi: 10.2174/157016209789973691. Curr HIV Res. 2009. PMID: 19929794

5

Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.

Curran A, Gutirerrez M, Deig E, Mateo G, Lopez RM, Imaz A, Crespo M, Ocaña I, Domingo P, Ribera E. Curran A, et al. J Antimicrob Chemother. 2010 Oct;65(10):2195-203. doi: 10.1093/jac/dkq295. Epub 2010 Aug 16. J Antimicrob Chemother. 2010. PMID: 20713406

6

Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.

Imaz A, Llibre JM, Mora M, Mateo G, Camacho A, Blanco JR, Curran A, Santos JR, Caballero E, Bravo I, Gayá F, Domingo P, Rivero A, Falcó V, Clotet B, Ribera E. Imaz A, et al. Among authors: curran a. J Antimicrob Chemother. 2011 Feb;66(2):358-62. doi: 10.1093/jac/dkq432. Epub 2010 Dec 14. J Antimicrob Chemother. 2011. PMID: 21172789

7

From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.

Curran A, Ribera E. Curran A, et al. Expert Opin Drug Saf. 2011 May;10(3):389-406. doi: 10.1517/14740338.2011.542145. Epub 2011 Jan 17. Expert Opin Drug Saf. 2011. PMID: 21235431 Review.

8

Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.

Saumoy M, Ordoñez-Llanos J, Martínez E, Barragán P, Ribera E, Bonet R, Knobel H, Negredo E, Loncá M, Curran A, Gatell JM, Podzamczer D; Bicombo-met Substudy Team. Saumoy M, et al. Among authors: curran a. Antivir Ther. 2011;16(4):459-68. doi: 10.3851/IMP1785. Antivir Ther. 2011. PMID: 21685533 Clinical Trial.

9

Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.

Curran A, Martinez E, Saumoy M, del Rio L, Crespo M, Larrousse M, Podzamczer D, Burgos J, Lonca M, Domingo P, Gatell JM, Ribera E. Curran A, et al. AIDS. 2012 Feb 20;26(4):475-81. doi: 10.1097/QAD.0b013e32834f3507. AIDS. 2012. PMID: 22112606 Clinical Trial.

10

HIV and TB coinfection: using adjusted doses of lopinavir/ritonavir with rifampin.

Curran A, Ribera E. Curran A, et al. Expert Rev Anti Infect Ther. 2011 Dec;9(12):1115-8. doi: 10.1586/eri.11.143. Expert Rev Anti Infect Ther. 2011. PMID: 22114961

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

510 results

Search Page

Filters